Correspondingly, levels of soluble ST2, an IL-33 decoy receptor, are significantly increased in MCI serum (Fu et al., 2016; Saresella et al., 2020) and also in AD serum (Saresella et al., 2020), suggesting that normalizing IL-33 may be a relevant strategy in AD, yet must occur very early in disease course to be effective. The gene discussed is IL1RL1; the disease is Alzheimer disease.